Previous neuropathological studies have suggested that individuals with ‘pure’ LATE (where the sole presence of LATE-NC accounts for cognitive impairment), show slower clinical decline compared to those with ‘pure’ Alzheimer’s disease pathology, also known as Alzheimer’s disease neuropathological change (ADNC) [where the combined presence of hyperphosphorylated tau, amyloid-β protein and neuritic plaques account for cognitive impairment (Boyle et al., 2017; Josephs et al., 2017)]. This evidence concerns the gene MAPT and Cognitive impairment.